Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells 2,500 Shares of Stock

Key Points

• Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of stock at an average price of $118.53, totaling $296,325, reducing his ownership by 1.54% to 160,110 shares.
• The company reported $2.01 EPS for the last quarter, surpassing analyst expectations and achieving revenue of $7.08 billion, marking a 1.4% year-over-year increase.
• Gilead has announced a quarterly dividend of $0.79 per share, with a yield of 2.7%, set to be paid on September 29th to shareholders of record as of September 15th.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $296,325.00. Following the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This represents a 1.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.38 during mid-day trading on Monday, hitting $117.99. 4,474,821 shares of the stock traded hands, compared to its average volume of 8,342,074. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a twelve month low of $73.27 and a twelve month high of $121.83. The company has a market cap of $146.40 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The firm has a 50 day simple moving average of $111.88 and a two-hundred day simple moving average of $108.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's payout ratio is presently 62.95%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geneos Wealth Management Inc. lifted its holdings in Gilead Sciences by 6.7% during the 2nd quarter. Geneos Wealth Management Inc. now owns 50,601 shares of the biopharmaceutical company's stock worth $5,610,000 after buying an additional 3,167 shares during the period. Westwood Holdings Group Inc. lifted its holdings in Gilead Sciences by 3.5% during the 2nd quarter. Westwood Holdings Group Inc. now owns 334,052 shares of the biopharmaceutical company's stock worth $37,036,000 after buying an additional 11,145 shares during the period. Kestra Investment Management LLC lifted its holdings in Gilead Sciences by 683.2% during the 2nd quarter. Kestra Investment Management LLC now owns 10,949 shares of the biopharmaceutical company's stock worth $1,214,000 after buying an additional 9,551 shares during the period. Rexford Capital Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth about $696,000. Finally, Evergreen Capital Management LLC lifted its holdings in Gilead Sciences by 16.4% during the 2nd quarter. Evergreen Capital Management LLC now owns 24,072 shares of the biopharmaceutical company's stock worth $2,669,000 after buying an additional 3,393 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on GILD shares. Oppenheimer reduced their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald started coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Finally, Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus price target of $114.82.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.